Purity determination of pharmaceuticals by thermal analysis

With customers accelerating their move towards digital (triggered by Covid-19), omnichannel thinking should be a key dimension of your 2023 business planning.

The boom of virtual and augmented reality in the healthcare and pharmaceutical industries is a major growth area for XR. However, there are still many regulatory challenges to overcome, and there are plenty of questions still to be answered.

The focus on accelerated development of new modalities for advanced therapies and challenges with complex drug candidates has driven the adoption of novel concepts and technologies in pharmaceutical development and manufacturing.

There are approximately 7,000 distinct rare diseases affecting 350 million people worldwide, approximately 80 percent of which are caused by faulty genes. Scientific advances such as the CRISPR/Cas9 genome-engineering system have simplified the pharmaceutical and biotech industry’s ability to develop gene therapies, especially for single gene mutation disorders. The US Food and Drug Administration (FDA) has more than 700 active Investigational New Drug Applications (INDs) for gene and cell therapies and in 2017, the FDA approved two cell-based gene therapies and it is anticipated that gene therapy will become a mainstay treatment for many rare diseases.